Rapid Fire Saturday 19 May 08:00 - 09:32 Salle des Princes
J. Rehak, E. Fric, M. Rehak, B. Babkova, Z. Pracharova, O. Chrapek,
CZECH REPUBLIC
Central retinal vein occlusion - anticoagulant treatment with warfarin
Purpose: It is generally thought that don't exist effective treatment of central retinal vein occlusion (CRVO). This study evaluate the effect of anticoagulant treatment with warfarin on visual acuity (VA) in the therapy of CRVO and compare the results with no treated group. Settings: Prospective study. Methods: We performed treatment of 60 eyes with CRVO using warfarin. The patients were divided into two basic groups: ischemic (10) and nonischemic (50) CRVO. VA in nonischemic CRVO was also evaluated separately in group A - eyes with initial VA 6/60 and worse (15) and group B - eyes with initial VA 6/12 and better (19). Convertion of nonischemic to ischemic CRVO and incidence of neovascular glaucoma (NVG) was also evaluated. The results were statistically evaluated and compared with no treated CRVO (data published by Quinlan). Pretrombosis as an initial stadium of nonischemic CRVO is defined as a newly introduced term. Results: As a failure is considered the incidence of final VA 6/60 and worse: nonischemic CRVO: 12 (24%), group A: 5 (33%), group B:1 (5%) - the result in nonischemic CRVO and in group A are significantly better than 50% and 88% in nontreated groups. The result in group B: 1(5%) is better than in nontreated group (21%) but is not statistically significant as well as number of conversions to ischemic CRVO: 3 (6%) in our group to 10% in nontreated group.The result in ischemic CRVO (100%) is almost the same as in nontreated group (93%). Conclusions: Anticoagulant therapy with warfarin in the case of nonischemic CRVO brings significantly better visual result when compared with nontreated eyes. In the case of ischemic CRVO this therapy don't influence the final VA. This therapy also reduces occurance of conversion of nonichemic CRVO to ischemic one but without statistically significance.
